US Markets for Nonvascular Stents
This article was originally published in Start Up
Lately, drug-eluting stents have downright monopolized all discussions of new stent technology, but there's a whole world of stenting outside of the interventional cardiology suite, and some of these clinical applications represent healthy markets for small companies. According to a report published in June by the Medtech Insight division of Windhover Information, "US Markets for Nonvascular Stents," sales of stents in several non-cardiology niche markets totaled approximately $152 million in 2005, a year in which stents were used in approximately 491,000 nonvascular endoluminal recanalization procedures. Overall, sales of these products are expected to grow at an annual compound rate of almost 3%, reaching approximately $174 million in the year 2010.
You may also be interested in...
With most peripheral device companies focusing on interventionalists, Vascular Architects is changing course to make the forgotten vascular surgeon their primary customer.
Alveolus Inc. is focused on stenting obstructed airways and other nonvascular lumens with a removable self-expanding metal stent that can be placed with direct visualization. The company believes that in addition to improving the quality of life for terminally ill cancer patients, its products can potentially be used as temporary, minimally invasive treatments in many diseases characterized by benign lumenal obstructions.
Vascular Architects Inc. has developed two product platforms for treating peripheral vascular occlusive disease. The first, already on the market in the US and Europe, is a non-motorized Remote Endarterectomy debulking device. The second is a covered stent that reduces the potential for intimal hyperplasia, and a unique delivery system that allows interventionalists to visualize the stent in place before deploying it.